我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

促红细胞生成素对慢性心力衰竭患者生活质量和住院时间的影响

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2013年第4期
页码:
436-438
栏目:
临床研究
出版日期:
2013-07-25

文章信息/Info

Title:
Effect of erythropoietin on quality of life and hospitalization time in patients with chronic heart failure
作者:
吴锦波; 王志兵; 袁 诚
(东莞市虎门中医院内科，广东 东莞 5239382)
Author(s):
WU Jinbo;  WANG Zhibing;  YUAN Cheng
(Department of Internal Medicine, Humen Hospital of TCM, Dongguan 523938, Guangdong, China)
关键词:
心力衰竭; 慢性; 促红细胞生成素; 生活质量; 住院时间
Keywords:
heart failure;  congestive;  erythropoietin;  quality of life;  hospitalization
分类号:
R541.6
DOI:
-
文献标识码:
A
摘要:
目的:观察促红细胞生成素（erythropoietin,EPO）对慢性心力衰竭（chronic heart failure,CHF）患者生活质量和住院时间的影响。方法:将80例CHF患者随机分成常规治疗组(对照组)和试药组（各40例），记录治疗前后患者的明尼苏达心力衰竭生活质量评分，分析比较住院时间和再住院率。结果:试药组治疗前后生活质量评分的改善显著优于对照组(P<0.05), 住院时间和再住院率均少于对照组(均P<0.05)。结论: EPO治疗CHF能显著提高患者生活质量，减少住院时间。
Abstract:
AIM:To observe the effect of erythropoietin (EPO) on the quality of life and hospitalization time in patients with chronic heart failure (CHF). METHODS: Eighty CHF patients were randomly equally divided into two groups: 40 patients in the control group treated with standard CHF medications and 40 patients in the EPO group treated with standard CHF medications plus EPO. The Minnesota Heart Failure Quality of Life Scale was measured before and after treatment and hospitalization days and rates of rehospitalization were compared between groups. RESULTS: After treatment, improvement of the Minnesota Heart Failure Quality of Life Scale in EPO group was higher than in control group (P<005) and days of hospitalization and rate of rehospitalization in EPO group were lower than those in control group (all P<005). CONCLUSION: Treatment with EPO can improve quality of life and reduce hospitalization days and rehospitalization rate in CHF patients.

参考文献/References

[1]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志, 2007,35(12):1076-1095.

[2]田 娟.早期循序渐进运动训练对慢性心力衰竭患者心功能和住院时间的影响[J].广东医学,2012,33(6):792-794.

[3]Zaya M,Phan A,Schwarz ER. Predictors of rehospitalization in patients with chronic heart failure[J].World J Cardiol,2012,4(2):23-30.

[4]Silverberg DS,Wexler D,Sheps D,et al.The effect of correction of mild anemia in severe,resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron:a randomized controlled study[J].J Am Coll Cardiol,2001,37(7):1775-1780.

[5]Mancini DM,Katz SD,Long CC,et al.Effect of erythropo ietin on exercise capacity in patients with moderate to severe chronic heart failure[J].Circulation,2003,107(2):294-299.

[6]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2002,30(1):7-23.

[7]Van der Meet P,Voors AA,Lipsic E,et al.Erythropoietin in cardiovascular disease[J].Eur Heart J,2004, 25(4):285-291.

[8]Westenbrink BD,Lipsic E,Van der Meet P,et al.Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization[J].Eur Heart J,2007,28(16):2018-2027.

备注/Memo

备注/Memo:
收稿日期：2012-12-12.基金项目：东莞市科技局基金项目资助（201110515029140） 作者简介：吴锦波，主治医师，博士 Email：wujinbo@ymail.com
更新日期/Last Update: 2013-07-29